In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Investigative Radiology
- Vol. 41 (3) , 305-312
- https://doi.org/10.1097/01.rli.0000199281.60135.6a
Abstract
Objectives: This study explored the use of 19F spectroscopy and imaging with targeted perfluorocarbon nanoparticles for the simultaneous identification of multiple biosignatures at 1.5 T. Materials and Methods: Two nanoparticle emulsions with perfluoro-15-crown-5-ether (CE) or perfluorooctylbromide (PFOB) cores were targeted in vitro to fibrin clot phantoms (n = 12) in 4 progressive ratios using biotin–avidin interactions. The CE nanoparticles incorporated gadolinium. Fluorine images were acquired using steady-state gradient-echo techniques; spectra using volume-selective and nonselective sampling. Results: On conventional T1-weighted imaging, clots with CE nanoparticles enhanced as expected, with intensity decreasing monotonically with CE concentration. All clots were visualized using wide bandwidth fluorine imaging, while restricted bandwidth excitation permitted independent imaging of CE or PFOB nanoparticles. Furthermore, 19F imaging and spectroscopy allowed visual and quantitative confirmation of relative perfluorocarbon nanoparticle distributions. Conclusions: 19F MRI/S molecular imaging of perfluorocarbon nanoparticles in vitro suggests that noninvasive phenotypic characterization of pathologic biosignatures is feasible at clinical field strengths.Keywords
This publication has 42 references indexed in Scilit:
- MR imaging staging of pelvic lymph nodesMagnetic Resonance Imaging Clinics of North America, 2004
- Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With α v β 3 -Integrin–Targeted NanoparticlesCirculation, 2003
- Novel MRI Contrast Agent for Molecular Imaging of FibrinCirculation, 2001
- Magnetic resonance contrast enhancement of neovasculature with ?v?3-targeted nanoparticlesMagnetic Resonance in Medicine, 2000
- Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imagingNature Medicine, 1998
- LIVER-SPECIFIC MR IMAGING CONTRAST AGENTSRadiologic Clinics of North America, 1998
- Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).American Journal of Roentgenology, 1995
- Investigation of Mechanisms Influencing the Accumulation of Ultrasmall Superparamagnetic Iron Oxide Particles in Lymph NodesInvestigative Radiology, 1995
- AMI-227-enhanced MR lymphography: usefulness for differentiating reactive from tumor-bearing lymph nodes.Radiology, 1994
- Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging.Radiology, 1990